Editorial: Biomarkers in structural cardiovascular disease: insights into screening, diagnosis and prognosis.

Front Cardiovasc Med

Instituto do Coração (InCor), Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HC FMUSP), São Paulo, Brazil.

Published: November 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702537PMC
http://dx.doi.org/10.3389/fcvm.2023.1337376DOI Listing

Publication Analysis

Top Keywords

editorial biomarkers
4
biomarkers structural
4
structural cardiovascular
4
cardiovascular disease
4
disease insights
4
insights screening
4
screening diagnosis
4
diagnosis prognosis
4
editorial
1
structural
1

Similar Publications

Editorial: Way to Go with OSA Biomarkers.

Sleep

January 2025

Professor of Medicine and Physiology & Biophysics, University Hospitals, Cleveland Medical Center, Case Western University School of Medicine, Cleveland OH, USA.

View Article and Find Full Text PDF

Introduction: Chronic inflammation is a major risk factor for coronary artery disease (CAD). Currently, the inflammatory cardiovascular risk is assessed via C-reactive protein (CRP) levels measured using a high-sensitivity assay (hsCRP). Monomeric CRP (mCRP) is a locally produced form of CRP that has emerged as a potential biomarker of inflammation.

View Article and Find Full Text PDF

CD56 CD16 cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.

Front Immunol

January 2025

Team Immunity and Cancer, Cancer Research Center of Marseille (CRCM), Inserm U1068, CNRS UMR7258, Paoli-Calmettes Institute, University of Aix-Marseille UM105, Marseille, France.

Introduction: Acute myeloid leukemia (AML) is a rare haematological cancer with poor 5-years overall survival (OS) and high relapse rate. Leukemic cells are sensitive to Natural Killer (NK) cell mediated killing. However, NK cells are highly impaired in AML, which promote AML immune escape from NK cell immune surveillance.

View Article and Find Full Text PDF

Improving postoperative outcomes in patients with pancreatic cancer: Inflammatory and nutritional biomarkers.

World J Clin Oncol

January 2025

Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan.

This editorial assesses the prognostic value of preoperative inflammatory and nutritional biomarkers in patients undergoing surgical resection for pancreatic cancer. Lu evaluated the ability of seven biomarkers to predict postoperative recovery and long-term outcomes. These biomarkers were albumin-to-globulin ratio, prognostic nutritional index (PNI), systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, nutritional risk index, and geriatric nutritional risk index.

View Article and Find Full Text PDF

Pancreatic cancer is usually associated with a poor prognosis. Surgery is the main curative treatment but pancreatic operations are aggressive and new tools that help clinicians to predict surgical and prognostic outcomes are necessary. Lu recently published a retrospective, single centre cohort study evaluating the impact of seven nutritional and inflammatory markers in pancreatic cancer surgical patients: The albumin-to-globulin ratio, prognostic nutritional index (PNI), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), nutritional risk index, and the geriatric nutritional risk index.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!